
|Videos|July 19, 2023
Rationale for Treatment of MDS With Luspatercept
Author(s)Amy Dezern, MD, MHS
Dr Amy Dezern reviews the mechanism of action of luspatercept and its rationale for use in MDS.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5































